Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRELI domain containing 3B pseudogene 11 (PRELID3BP11) is a processed pseudogene in humans. It shares sequence similarity with the functional PRELI domain containing 3B gene but does not produce a functional protein product and has lost its protein-coding capability. Classified as a pseudogene, it does not have a known biological function and is not recognized as a therapeutic target, receptor, enzyme, or transporter. Key details supporting this classification: - The gene is listed as a pseudogene by multiple authoritative sources, including NCBI, HGNC, GeneCards, and others. - No biological function, disease association, or interaction with drugs has been described. - The locus is a retrocopy (processed pseudogene) of the parental gene PRELID3B and is not functional as a protein-coding gene. - It is not considered a therapeutic target. There are no apparent misspellings or major errors in the naming; however, since it is a pseudogene, it does not meet the criteria typically required for a "target" molecule in drug discovery or therapeutic contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PRELI domain containing 3B pseudogene 11 (PRELID3BP11).